James West: John, welcome back to the show.
John Fowler: James, always a pleasure. Thanks for having me back again.
James West: It’s been a while since we’ve chatted, John, and you’ve had some significant developments in Supreme Pharmaceuticals. Why don’t you start with the listing on the TSX Venture?
John Fowler: Absolutely. So moving from the CSC to the Venture has always been something in our plan, something as part of our corporate progression. We’re eminently thankful for the CSC for the time we had there. A lot of investors may not be aware that for early stage cannabis companies, the CSC was one of the only ways to access public capital prior to reaching licensing milestones. So with our trajectory, it was essential we were able to go on to an entrepreneurial exchange, keep our …